Stratrix
Company data sheet · Bristol Myers Squibb

Bristol Myers Squibb: ahead of almost everyone like it.

Industry
Pharmaceutical Preparations Manufacturing
Headquarters
United States
Ticker
BMY (NYSE)
Sources
SEC filings (1994–2026), Stratrix's verified Decision Cases, market data and official economic statistics for the United States
Data as of
November 15, 2026
  1. Ahead of almost everyone like it. From 2016 to 2025, its revenue grew 148% in US dollars; the median among 181 large manufacturers grew 49%. It outgrew 84% of them.
  2. Leaders came and went. Bristol Myers Squibb filed 37 leadership changes since 2016, more than 89% of large manufacturers (the median is 20). The day after each, its shares moved a median 0.0 points against its sector. The news was rarely news.
  3. One decision on record. Stratrix has verified one of Bristol Myers Squibb's big decisions, each with what happened next.

Financial results

Fiscal yearRevenueNet income
2016$19.4 billion$4.5 billion
2017$20.8 billion$1 billion
2018$22.6 billion$4.9 billion
2019$26.1 billion$3.4 billion
2020$42.5 billion−$9 billion
2021$46.4 billion$7 billion
2022$46.2 billion$6.3 billion
2023$45 billion$8 billion
2024$48.3 billion−$8.9 billion
2025$48.2 billion$7.1 billion

As reported in its annual filings. Losses in red.

Stratrix Decision Cases

Has Bristol Myers Squibb had layoffs?

Headcount, as reported

Annual reportEmployeesAs of
10-K for 2023approximately 34,100December 31, 2023
10-K for 2024approximately 34,100As of December 31, 2024
10-K for 2025approximately 32,500December 31, 2025

Job cuts, severance and restructuring

  1. The company recorded a new restructuring plan in 2023, with provision for restructuring of $365 million in other (income)/expense. 2023

    “Provision for restructuring includes exit and other costs primarily related to certain restructuring activities including a new plan in 2023 discussed further in "Item 8. Financial Statements and Supplementary Data—Note 6. Restructuring."” 10-K for 2023
Reported in the company's financial data (XBRL), each linked to its filing
Fiscal year endedSeverance costsRestructuring chargesCash paid for restructuring
2016-12-31$97 million$109 million$120 million
2017-12-31$267 million$293 million$239 million
2018-12-31$87 million$131 million$219 million
2019-12-31$273 million$301 million$151 million
2020-12-31$457 million$530 million$418 million
2021-12-31$159 million$169 million$199 million
2022-12-31$69 million$75 million$122 million
2023-12-31$350 million$365 million$225 million
2024-12-31$623 million$635 million$520 million
2025-12-31$548 million$563 million$558 million

Bristol Myers Squibb has filed no restructuring notice (Form 8-K, Item 2.05) since 2016. Companies file one only for a cut they judge material, so many announced layoffs never appear as one. This page shows what the company reported to the SEC, not news reports or state layoff notices.

What has Bristol Myers Squibb acquired?

Deals its annual reports describe

BusinessDealWhenValue
Mirati
“(i) the acquisition of Mirati, which was completed in January 2024; (ii) the planned acquisitions of Karuna and RayzeBio, which were announced in December 2023; and (iii) a global strategic collaboration agreement with SystImmune, which was announced in December 2023.” 10-K for 2023
acquisitioncompleted in January 2024—
Karuna
“(ii) the planned acquisitions of Karuna and RayzeBio, which were announced in December 2023; and (iii) a global strategic collaboration agreement with SystImmune, which was announced in December 2023.” 10-K for 2023
agreed acquisitionannounced in December 2023—
RayzeBio
“(ii) the planned acquisitions of Karuna and RayzeBio, which were announced in December 2023; and (iii) a global strategic collaboration agreement with SystImmune, which was announced in December 2023.” 10-K for 2023
agreed acquisitionannounced in December 2023—
Turning Point
“partially offset by the acquisition of Turning Point ($3.2 billion net of cash acquired) in 2022.” 10-K for 2023
acquisition2022$3.2 billion net of cash acquired
Mavacamten rights buy-out
“Mavacamten rights buy-out (Note 4) $ 445 $ — Orum upfront payment (Note 4) 100 — Mavacamten royalty extinguishment (Note 4) — 295 Dragonfly milestone and opt-in license fee — 200 Evotec designation and opt-in license fees 90 — BridgeBio upfront collaboration fee — 90 Prothena opt-in license fee 55 Zenas upfront license fee 50 — Immatics upfront license and opt-in fee (Note 4) 15 150 Other 158 80 Acquired IPRD $ 913 $ 815 Refer to “Item 8. Financial Statements and Supplementary Data—Note 3. Alliances” and “—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements” for additional information.” 10-K for 2023
acquisition——
diabetes business
“Royalties have continued to represent a significant percentage of our pretax income, including royalties related to the divestiture of our diabetes business (including the transfer of certain future royalty rights pertaining to Amylin, Onglyza* and Farxiga* product sales), out-licensed intellectual property and the Merck patent infringement settlement.” 10-K for 2023
divestiture——
SystImmune
“We also entered into a strategic collaboration with SystImmune, to co-develop and co-commercialize izalontamab brengitecan (iza-bren or BL-B01D1), a bispecific topoisomerase inhibitor-based anti-body drug conjugate.” 10-K for 2024
agreed acquisition——
Orbital Therapeutics
“In 2025, the Company (i) acquired Orbital Therapeutics, which provided the Company with full rights to OTX-201, a preclinical in vivo CAR T-cell therapy currently in IND-enabling studies for autoimmune disease, (ii) entered into a strategic collaboration with BioNTech to co-develop and co-commercialize BioNTech's investigational bispecific antibody pumitamig (BNT327/BMS986545) across multiple solid tumor types, (iii) acquired a global exclusive license from Philochem for OncoACP3, a radiopharmaceutical therapeutic and diagnostic agent targeting prostate cancer, and (iv) expanded our development and manufacturing capabilities by opening a new radiopharmaceutical facility in Indianapolis, Indiana, which will support RPTs acquired in connection with the RayzeBio acquisition.” 10-K for 2025
acquisition2025—
Reported in the company's financial data (XBRL), each linked to its filing
Fiscal year endedCash paid for acquisitions (net of cash acquired)Goodwill from acquisitions
2016-12-31$359 million—
2017-12-31$726 million—
2018-12-31$2.37 billion—
2019-12-31$24.78 billion—
2020-12-31$13.08 billion—
2021-12-31$1.61 billion—
2022-12-31$4.29 billion—
2023-12-31$1.17 billion$0
2024-12-31$21.82 billion$580 million
2025-12-31$3.94 billion$0

Deal filings since 2016

Who are Bristol Myers Squibb's competitors?

Who Bristol Myers Squibb names

Bristol Myers Squibb’s annual reports for 2023 to 2025 describe its competition by kind of business and do not name competing companies.

Who names Bristol Myers Squibb

Companies whose own annual reports name Bristol Myers Squibb as a competitor.

  1. BeOne Medicines · 2025

    “Bristol Myers Squibb OPDIVO U.S., Europe, Asia Pacific & China” 10-K for 2025
  2. Legend Biotech names it as “Bristol-Myers Squibb” · 2025

    “Bristol-Myers Squibb's anti-CD19 CAR-T therapy, Breyanzi ("liso-cel"), as well as anti-BCMA CAR-T therapy, Abecma ("ide-cel"), in collaboration with bluebird bio, are also marketed CAR-T products.” 20-F for 2025
  3. Regeneron Pharmaceuticals names it as “Bristol-Myers Squibb” · 2025

    “There are several competitors that are marketing and/or developing antibodies against PD-1 and/or PDL-1 (some of which were approved in the relevant indications and commercialized before Libtayo), including Merck's Keytruda ® (pembrolizumab), Bristol-Myers Squibb's Opdivo ® (nivolumab), Roche's Tecentriq ® (atezolizumab), AstraZeneca's Imfinzi ® (durvalumab), and Sun Pharma's Unloxcyt ™ (cosibelimab).” 10-K for 2025
  4. Seagen names it as “Bristol-Myers Squibb” · 2022

    “Bristol-Myers Squibb's, or BMS's nivolumab and Merck's pembrolizumab are approved for the treatment of certain patients with relapsed or refractory classical Hodgkin lymphoma, and Acrotech Biopharma's pralatrexate and belinostat are approved for relapsed or refractory systemic anaplastic large cell lymphoma, or sALCL, among other T-cell lymphomas.” 10-K for 2022

What are Bristol Myers Squibb's subsidiaries?

Subsidiaries it lists

SubsidiaryJurisdiction
1096271 BC ULCCanada
2seventy bio, IncUnited States
2seventy bio Securities CorporationUnited States
345 Park LLCUnited States
9643435 Canada Inc.Canada
Abraxis BioScience Australia Pty Ltd.Australia
Abraxis BioScience International Holding Company, Inc.United States
Abraxis BioScience, Inc.United States
Abraxis BioScience, LLCUnited States
AbVitro LLCUnited States
Adnexus, a Bristol-Myers Squibb R&D CompanyUnited States
AHI Investment, LLCUnited States
Allard Labs Acquisition G.P.United States
Amira Pharmaceuticals, Inc.United States
Apothecon LLCUnited States
Blisa Acquisition G.P.United States
BMS Bermuda Nominees L.L.C.United States
BMS Forex CompanyUnited States
BMS Holdings Netherlands Beta B.V.Netherlands
BMS Ireland Capital Funding Designated Activity CompanyIreland
BMS Korea Holdings L.L.C.United States
BMS Latin American Nominees L.L.C.United States
BMS Netherlands Operations B.V.Netherlands
BMS Pharmaceutical Korea LimitedKorea, Republic of
BMS Pharmaceuticals Germany Holdings B.V.Netherlands
BMS Pharmaceuticals International Holdings Netherlands B.V.Netherlands
BMS Pharmaceuticals Korea Holdings B.V.Netherlands
BMS Pharmaceuticals Mexico Holdings B.V.Netherlands
BMS Pharmaceuticals Netherlands Holdings B.V.Netherlands
BMS Real Estate LLCUnited States
BMS Spain Investments LLCUnited States
BMS Strategic Portfolio Investments Holdings, Inc.United States
Bristol Laboratories International, S.A.United States
Bristol Laboratories Medical Information Systems Inc.United States
Bristol-Myers (Andes) L.L.C.United States
Bristol-Myers Squibb (Beijing) Innovation Pharmaceutical Technology Co., Ltd.China
Bristol-Myers (Private) LimitedZimbabwe
Bristol-Myers Overseas CorporationUnited States
Bristol-Myers Squibb (China) Investment Co., Ltd.China
Bristol-Myers Squibb (China) Pharmaceuticals Co., Ltd.China
Bristol-Myers Squibb (Israel) Ltd.Israel
Bristol-Myers Squibb (NZ) LimitedNew Zealand
Bristol-Myers Squibb (Proprietary) LimitedSouth Africa
Bristol-Myers Squibb (Shanghai) Trading Co. Ltd.China
Bristol-Myers Squibb (Singapore) Pte. LimitedSingapore
Bristol-Myers Squibb (Taiwan) Ltd.Taiwan Province of China
Bristol-Myers Squibb (West Indies) Ltd.United States
Bristol-Myers Squibb A.E.Greece
Bristol-Myers Squibb AktiebolagSweden
Bristol-Myers Squibb Argentina S. R. L.Argentina
Bristol-Myers Squibb Australia Pty. Ltd.Australia
Bristol-Myers Squibb B.V.Netherlands
Bristol-Myers Squibb Belgium S.A.Belgium
Bristol-Myers Squibb Business Services India Private LimitedIndia
Bristol-Myers Squibb Business Services LimitedUnited Kingdom
Bristol-Myers Squibb Canada Co.Canada
Bristol-Myers Squibb Canada International LimitedCanada
Bristol-Myers Squibb de Colombia S.A.Colombia
Bristol-Myers Squibb de Mexico, S. de R.L. de C.V.Mexico
Bristol-Myers Squibb Delta Company LimitedIreland
Bristol-Myers Squibb Denmark Filial of Bristol-Myers Squibb ABDenmark
Bristol-Myers Squibb Egypt, LLCEgypt
Bristol-Myers Squibb EMEA SarlFrance
Bristol-Myers Squibb Epsilon Holdings Unlimited CompanyIreland
Bristol-Myers Squibb Farmaceutica Ltda.Brazil
Bristol-Myers Squibb Farmaceutica Portuguesa S.A.Portugal
Bristol-Myers Squibb Ges mbH.Austria
Bristol-Myers Squibb GmbH & Co. KGaAGermany
Bristol-Myers Squibb Hanbai K.KJapan
Bristol-Myers Squibb Holding Germany GmbH & Co. KGGermany
Bristol-Myers Squibb Holdings 2002 LimitedUnited Kingdom
Bristol-Myers Squibb Holdings Germany Verwaltungs GmbHGermany
Bristol-Myers Squibb Holdings Ireland Unlimited CompanyIreland
Bristol-Myers Squibb Holdings LimitedUnited Kingdom
Bristol-Myers Squibb Holdings Pharma Ltd. Liability CompanySwitzerland
Bristol-Myers Squibb Ilaclari, Inc.United States
Bristol-Myers Squibb India Pvt. LimitedIndia
Bristol-Myers Squibb International Company Unlimited CompanyIreland
Bristol-Myers Squibb International CorporationUnited States
Bristol-Myers Squibb Investco, L.L.C.United States
Bristol-Myers Squibb K.K.Japan
Bristol-Myers Squibb Kft.Hungary
Bristol-Myers Squibb Limited Liability CompanyRussian Federation
Bristol-Myers Squibb Manufacturing Company Unlimited CompanyIreland
Bristol-Myers Squibb Marketing Services S.R.L.Romania
Bristol-Myers Squibb MEA GmbHSwitzerland
Bristol-Myers Squibb Middle East & Africa FZ-LLCUnited Arab Emirates
Bristol-Myers Squibb Norway Holdings Inc.United States
Bristol-Myers Squibb Norway ASNorway
Bristol-Myers Squibb Peru S.A.Peru
Bristol-Myers Squibb Pharma (HK) LtdHong Kong
Bristol-Myers Squibb Pharma (Thailand) LimitedThailand
Bristol-Myers Squibb Pharma CompanyUnited States
Bristol-Myers Squibb Pharma EEIGIreland
Bristol-Myers Squibb Pharma Holding Company, LLCUnited States
Bristol-Myers Squibb Pharma Ventures CorporationUnited States
Bristol-Myers Squibb Pharmaceuticals LimitedUnited Kingdom
Bristol-Myers Squibb Pharmaceuticals Unlimited CompanyIreland
Bristol-Myers Squibb Polska Sp. z o.o.Poland
Bristol-Myers Squibb Products S.A.Switzerland
Bristol-Myers Squibb Puerto Rico, Inc.United States
Bristol Myers Squibb Regional Headquarter CompanySaudi Arabia
Bristol-Myers Squibb Romania S.R.L.Romania
Bristol-Myers Squibb S.r.l.Italy
Bristol-Myers Squibb SASwitzerland
Bristol-Myers Squibb SASFrance
Bristol-Myers Squibb Service Ltd.Bermuda
Bristol-Myers Squibb Services Sp. z o.o.Poland
Bristol-Myers Squibb Services Unlimited CompanyIreland
Bristol-Myers Squibb Spol. s r.o.Czech Republic
Bristol-Myers Squibb TGF Beta Inc.Canada
Bristol-Myers Squibb Trustees Ltd.United Kingdom
Bristol-Myers Squibb Verwaltungs GmbHGermany
Bristol-Myers Squibb, S.A.U.Spain
Bristol-Myers Squibb/Astrazeneca EEIGUnited Kingdom
Bristol-Myers Squibb/Pfizer EEIGIreland
Cardioxyl Pharmaceuticals, LLCUnited States
Celgene CAR LLCUnited States
Celgene Chemicals SarlSwitzerland
Celgene China Holdings LLCUnited States
Celgene CorporationUnited States
Celgene d.o.o.Croatia
Celgene Distribution B.V.Netherlands
Celgene Europe B.V.Netherlands
Celgene Europe LimitedUnited Kingdom
Celgene Financing Company, LLCUnited States
Celgene Global Holdings SarlSwitzerland
Celgene Holdings East CorporationUnited States
Celgene International Holdings CorporationUnited States
Celgene International Holdings Corporation, Prodruznica v SlovenijiSlovenia
Celgene International II SàrlSwitzerland
Celgene International Inc.United States
Celgene International SàrlSwitzerland
Celgene Kappa Holdings LLCUnited States
Celgene LimitedHong Kong
Celgene LimitedIreland
Celgene LimitedTaiwan Province of China
Celgene LimitedUnited Kingdom
Celgene Logistics SarlSwitzerland
Celgene Logistics Sarl (Sucursale Mexico)Mexico
Celgene Netherlands BVNetherlands
Celgene Netherlands Investment BVNetherlands
Celgene NJ Investment CoUnited States
Celgene Omicron Holdings, Inc.United States
Celgene Pharmaceutical (Shanghai) Company LimitedChina
Celgene Pty LimitedAustralia
Celgene Puerto Rico Distribution LLCPuerto Rico
Celgene Quanticel Research, Inc.United States
Celgene R&D SarlSwitzerland
Celgene Receptos LimitedUnited Kingdom

The list is long; these are the first 150 as the company lists them. From Exhibit 21 of the 10-K for 2025. Companies must list their significant subsidiaries there and may leave out smaller ones, so this is the company’s own list, not every entity it owns.

Layoffs, acquisitions, competitors and subsidiaries are read from Bristol Myers Squibb’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023), as of 2026-02-11.

The full data sheet · Data Plan

Everything behind these findings, ready for your board deck.

  • Market reaction to disclosed decisions: 53 decision filings since 2016, each linked to the SEC, with the share return against its sector and the US market the next day and the next year (39 with market data).
  • Economic context: 7 measures for the United States, every year since 2016, from the official sources.
  • Peer comparison: against 264 companies of its size in its sector.
  • Financial results: ten years of revenue, operating and net income, and every annual report, linked.
  • Methods and sources, so each number can be checked and cited.

The full data sheet downloads with the Data Plan. To see exactly what you get first, open the Boeing sample PDF or Excel.

Tools to try

More from Stratrix

The Business Model Wizard

Make the seven choices that define your model, test your numbers against real companies, and meet the rival AI would build against you.

Free · about twelve minutesBuild your Model Thesis →

Weekly email

Stratonomics, every Tuesday

One data story every Tuesday: what happened, what it means, and the figures you can quote. Free.

We'll email you a link to confirm. Unsubscribe anytime. Privacy policy.